{"links":{"html":"https://www.erudio.com/reports/acticca-1-nct02170090","json":"https://www.erudio.com/reports/acticca-1-nct02170090.json","markdown":"https://www.erudio.com/reports/acticca-1-nct02170090.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"acticca-1-02170090"}},"request":"https://www.erudio.com/contact?report=acticca-1-02170090"},"offer":{"cited_commentary_sources":29,"verified_hcp_statements":79,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":24,"optional":true,"price_per_verified_person_usd":15,"price_usd":360,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"acticca-1-nct02170090"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=acticca-1-02170090","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/acticca-1-nct02170090","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-01T15:43:40.035545Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":7,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":6,"title":"Primary endpoint: Disease free survival (DFS)"},{"claim_count":15,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":14,"title":"Secondary endpoints"},{"claim_count":14,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":8,"title":"Population and setting"},{"claim_count":32,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":26,"title":"The comparison"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":4,"title":"Safety and tolerability"},{"claim_count":12,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":2,"coverage":"discussed","id":"A1","source_count":2,"title":"Preserving GemCis for treatment after recurrence"},{"claim_count":15,"coverage":"discussed","id":"A2","source_count":9,"title":"Individualized adjuvant goals and selective escalation"},{"claim_count":16,"coverage":"discussed","id":"A3","source_count":2,"title":"Nodal work-up, treatment consequences and patient counseling"},{"claim_count":6,"coverage":"discussed","id":"A4","source_count":3,"title":"Local versus systemic control and chemoradiation alternatives"},{"claim_count":11,"coverage":"discussed","id":"A5","source_count":7,"title":"Alternative strategies: selection, added agents and perioperative sequencing"},{"claim_count":13,"coverage":"discussed","id":"A6","source_count":10,"title":"Confidence in existing adjuvant evidence and expectations for ACTICCA-1"}],"counts":{"cited_sources":31,"claims_by_expression_type":{"comparison":5,"experience":4,"interpretation":18,"opinion":24,"primary_context":5,"question":9,"restatement":9,"uncertainty":5},"claims_by_kind":{"protocol_statement":5,"source_observation":74},"clinician_statements":42,"evidence_units":73,"findings":7,"organisational_accounts":1,"people_cited":27,"people_identity_verified":24,"people_total":27,"screened_sources":65,"verified_claims":79},"findings_index":[{"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":11},"has_counterview":true,"limitations":3,"links":{"context":0,"support":14},"ma_question":true,"named_voices":8,"passages":14,"sources":14,"sources_by_kind":{"commentary":14}},"title":"No routine switch, but selective GemCis remains a contested option"},{"id":"F2","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":3,"views":5},"has_counterview":true,"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":5,"passages":8,"sources":7,"sources_by_kind":{"commentary":6,"media":1}},"title":"Early and numerical efficacy signals are not being read as an unequivocally positive primary comparison"},{"id":"F3","structure":{"claims":12,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":1,"views":7},"has_counterview":false,"limitations":3,"links":{"context":0,"support":13},"ma_question":true,"named_voices":6,"passages":7,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Individualization reflects recovery and tolerability, not a validated escalation rule"},{"id":"F4","structure":{"claims":15,"claims_by_group":{"comparisons":1,"experience":2,"questions":3,"restated":0,"views":9},"has_counterview":true,"limitations":3,"links":{"context":1,"support":15},"ma_question":true,"named_voices":10,"passages":15,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Nodal staging divides treatment-selection arguments from prognostic value"},{"id":"F5","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":2,"questions":1,"restated":1,"views":2},"has_counterview":true,"limitations":3,"links":{"context":1,"support":6},"ma_question":true,"named_voices":4,"passages":7,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Locoregional control and chemoradiation have rationales distinct from a survival claim"},{"id":"F6","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":0,"views":6},"has_counterview":false,"limitations":3,"links":{"context":1,"support":9},"ma_question":true,"named_voices":7,"passages":9,"sources":7,"sources_by_kind":{"commentary":5,"media":2}},"title":"Persistent recurrence prompts alternative-strategy questions, not proven replacements"},{"id":"F7","structure":{"claims":18,"claims_by_group":{"comparisons":2,"experience":0,"questions":4,"restated":5,"views":7},"has_counterview":false,"limitations":3,"links":{"context":0,"support":18},"ma_question":true,"named_voices":11,"passages":11,"sources":10,"sources_by_kind":{"commentary":9,"media":1}},"title":"Evolving comparators and long evidence timelines frame both anticipation and disappointment"}],"medical_affairs_question":"What patient profile, if any, justifies optional GemCis when speakers report additional toxicity and worry about preserving later treatment?","sections":{"analysis":[{"id":"section-1","level":2,"title":"No routine switch, but selective GemCis remains a contested option"},{"id":"section-2","level":2,"title":"Early and numerical efficacy signals are not being read as an unequivocally positive primary comparison"},{"id":"section-3","level":2,"title":"Individualization reflects recovery and tolerability, not a validated escalation rule"},{"id":"section-4","level":2,"title":"Nodal staging divides treatment-selection arguments from prognostic value"},{"id":"section-5","level":2,"title":"Locoregional control and chemoradiation have rationales distinct from a survival claim"},{"id":"section-6","level":2,"title":"Persistent recurrence prompts alternative-strategy questions, not proven replacements"},{"id":"section-7","level":2,"title":"Evolving comparators and long evidence timelines frame both anticipation and disappointment"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":7},{"id":"F3","shared_claims":1}],"id":"T1","label":"Primary endpoint: Disease free survival (DFS)"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":3},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":2}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":6},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":2},{"id":"F7","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":11},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":5},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":3},{"id":"F7","shared_claims":11}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":5},{"id":"F6","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F7","shared_claims":11}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-01T15:43:40.035545Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-01T15:56:52Z","record_hash":"d996a3c07381d6b042ccc19856f5db0650282156d237ac0a086293f46045d3fd","release_hash":"29599d8c0cea4b5a63a668ef2c7aab3f9bd8fcff29c199522a7653a12feab0a0","report_id":"erudio-nct02170090","run_id":"de71fa22-03d0-401b-8617-d09954d993ba","schema_version":"5.0","slug":"acticca-1-02170090","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"ACTICCA-1 asks whether adjuvant gemcitabine–cisplatin improves disease-free survival over standard care after curative-intent resection of cholangiocarcinoma or muscle-invasive gallbladder cancer; debate concerns selective GemCis use rather than routine replacement. The report cites 13 physicians, including five medical oncologists, six surgical oncologists and one radiation oncologist; another question is whether nodal staging changes treatment or informs prognosis. Which patients, if any, justify optional GemCis given reported toxicity and concerns about preserving later treatment? The sources reviewed for this edition place ACTICCA-1 results at ESMO 2026.","meta_description":"65 sources screened · 79 verified statements (42 from clinicians verified by NPI or staff page) from 31 sources · 7 findings. Updated Nov 1, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-47f1c48e036743ff0bb7","claim-aa9fe5d98f5cc7d537f8"],"id":"F7","paraphrase":"A surgical oncologist in a podcast discussion raised a design question about whether ACTICCA-1’s switch from observation to capecitabine could affect statistical power.","publication_caveats":{"reason":"Publication-specific caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"podcast","source_date":"2024-04-25","title":"Evolving comparators and long evidence timelines frame both anticipation and disappointment"},{"cited_claim_ids":["claim-0d4a7f138f72d7454749","claim-1835fe67ab0f450a9e47"],"id":"F3","paraphrase":"A podcast discussion asked how adjuvant evidence applies to resected perihilar cholangiocarcinoma and whether trial data could clarify treatment beyond capecitabine alone.","publication_caveats":["The clinical role of the speaker asking about perihilar cholangiocarcinoma is not confirmed in the sources reviewed for this edition."],"source_channel":"podcast","source_date":"2024-04-25","title":"Individualization reflects recovery and tolerability, not a validated escalation rule"}]},"publication":{"approved_at":"2026-11-01T15:56:52Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":65},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","81 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition do not represent all HCP discussion or establish the prevalence of any treatment preference.","Some passages were not fully assessed for clinician views. Discussion using unnamed references or other trial-name variants may be missing, including within sources considered for this edition.","Repeated posts and reposts must not be interpreted as additional independent HCP opinions or as evidence of agreement.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The primary publications provided here describe methods rather than observed results. Efficacy and toxicity figures in the report are attributed commentary, not an independently reconciled trial-results dataset.","Different median DFS values and OS p-values appear in the summaries, without enough information to explain whether they concern different analyses or populations.","Historical statements about standards, trial status and expected reporting retain their original timing. They do not establish actual reporting dates or changes in a speaker's position.","No assessed commentary addresses quality of life, biliary anastomotic function or biliary infection outcomes."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":1,"publication":1,"registry":1,"regulatory":0,"x_thread":26,"x_video":1,"youtube":0},"by_evidence_role":{"commentary":29,"methods":2},"count":31,"evidence_window":{"end":"2026-10-26","start":"2017-01-20"},"retrieval_snapshot":"2026-11-01T14:52:11.274574Z","timeline":[{"count":1,"week":"2017-W03"},{"count":1,"week":"2020-W18"},{"count":1,"week":"2020-W46"},{"count":1,"week":"2021-W19"},{"count":1,"week":"2022-W12"},{"count":1,"week":"2022-W50"},{"count":1,"week":"2023-W23"},{"count":1,"week":"2024-W17"},{"count":1,"week":"2024-W23"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2026-W42"},{"count":16,"week":"2026-W43"},{"count":2,"week":"2026-W44"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT02170090:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02170090:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:26228433","quote_policy":"short_quote_link_out"},{"id":"openfda:e11eeff7-bcaf-4bf1-8da8-88138e01af84:20260727","quote_policy":"short_quote_link_out"},{"id":"openfda:508496cb-3441-46b3-a4fe-e0d440e6adc6:20260624","quote_policy":"short_quote_link_out"},{"id":"openfda:0b59e98c-5b34-4b93-90f6-20526f4d4f88:20260721","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4ysesz2mn5ig5vitaq3qdjos-3myn2n3lqch25","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-axbq3ziqaqvmkd22kzwpiil4-3mypub3enfi2p","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3myhfs6b3dr2k","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520571132786331648","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6ba10a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1255638492945821697:ad900e43-d93e-4587-9099-5c74b55dcb95","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1299149366679150593:be2d04d1-5526-4815-8e14-2ad536ec34e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1327279266430672897:7f904cb8-84c8-4624-85c3-007b58efef31","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1392847265505714176:44d46da5-79a0-4baa-9f4f-432b040daccf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1419670332210884608:d919bb2f-931b-4245-9089-ba43de4d783d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1506771990472163328:74212369-1901-42b2-839b-edb1fe6eecc0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1539174554840580096:f9b6518b-b82a-4bec-88fd-d50d0a39c6e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1575336612418166784:c4111b05-af11-4ae8-ab55-e251444ada54","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1603704792592809988:11ab21ff-4dfe-43d1-82eb-725da9824cd8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665769630793596928:efdff68d-13b1-43ad-8edd-8e356a85c69f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1799274641669914858:6cf65de0-ee45-49ba-9f47-282c3579eb31","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1806368892001935863:32366ab3-a8a5-4180-87fa-b372f83fefaa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1858679222560321665:6af815ef-0967-4d40-b69a-5a3bfdc20690","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882915423341236281:73de63dd-404b-4f9a-81dc-efc4d53e9dbf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882972402956841081:e7bae946-8dab-44d9-b0cd-6d138e4b0e18","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102432534395306414:7a9f6256-9c22-449a-a219-2d895ac28e69","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104356268454686951:71766913-8c02-4a05-84b1-2e754abb5de3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108884570179301399:a79b8750-a086-4e34-9dfc-8efcf9f32358","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110616426516013484:036e0478-df2d-4449-aa1d-e7636b5aa4f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111079668140900657:8b976118-8e78-455b-9573-719468239e80","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112902368220287215:f730ae81-aa09-487b-9d1c-337436f579c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113208955425984822:d6849bc3-a98e-4a9a-9b10-335399bba83b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113645626760348023:572073cf-bf0e-437c-8972-31fd97f0bc92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113849458207359287:2b9e72c8-c76b-466f-b3c3-4a603a815933","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113910870309057020:78307397-9c4e-4746-87d1-451582aec93a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113912263627223294:9386dc3e-37fc-471c-8baa-2c71257485b4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113912837034705302:5753cfe9-e8e2-45c7-b70b-714336040419","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113912925849080204:16c47418-1937-4e14-b2b3-6fbdfadb151c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113913007096963272:3479eee5-e84e-401b-a5ef-6bae638f530f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113913264220336605:bebcff69-1f72-41a9-b981-5faa2c8f01c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113913315541835825:b9dfa5aa-dff9-483c-aa36-b27008bdfbf8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113913641116315761:99b138bf-0b51-414f-b9e3-cbe22db389e0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113914824292028558:d056106e-b5c5-40e6-8e9a-4f66b0ca6e08","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113915669330682189:e1caee13-9392-492f-a467-cd6aebcf9d6f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113917999157829974:b1ef4bd0-e08a-46a3-a8f2-c24669d8899d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113921269003665918:45068d30-fa3b-419c-b58d-d6bff742e94c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113944056074043455:2ac71407-0378-484a-8040-47145b9573a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113963094049218982:edbe6820-bca6-47b5-a3c2-239baa95291f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113964412751217096:93a88208-b110-4468-bab2-76dc8e8b603f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113976992513036429:ef87b6a8-9ad4-401d-aec5-2b3550da34df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113977098629001312:f5661f3a-4ec9-4c99-81a6-5b2932ccd70b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114023377933320614:e5496102-52e0-42df-8641-3fe53786d5fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114094799963750767:acf45e33-405a-4eb2-9b90-615086c2743b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114209294120022467:561419fe-5573-41ae-8237-824ef5028c83","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114244261948387349:62838b77-b110-48c8-944a-c0a268732645","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114335637935399012:667ce389-feb0-4db9-be37-a875499f13f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114376808871395594:677931a2-ea47-4129-b0b3-7183b6a896ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114427024810918180:ada48d14-2246-445c-aa2f-57e86d5d18f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114531656967311597:e9cfd02c-efcf-46cc-b801-9ffafc6aac46","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114605479326617894:955d5111-0c58-4049-bf5b-b66d9507bcae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114673179725533287:67a26f5c-0032-489c-99b6-3f44fc1959f1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114834610039234690:3caf614d-0c27-4905-bd65-91dc3cb9b1f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115707844431380618:a521f40e-343a-412a-894e-fd3a2a848357","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115708319859908782:70bdacf3-5a29-4bd5-b165-0f28345a7079","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115708390731063615:827d8775-8f17-45a1-b70f-4cfcbec240ab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115849276983238904:8c4b51fc-a996-4672-b652-0b536e6dfd50","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116107866297737266:306de7c4-8449-4e33-b4ea-0eb683d07c11","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:822532805880061952:312368c8-e3c8-40c7-84ce-4da53d7594a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:933541344911409152:f32e18ed-0a32-4cea-ae47-605b7f9e2453","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2114462329500741882","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":59,"x_video":1,"youtube":0},"by_evidence_role":{"commentary":65},"count":65,"evidence_window":{"end":"2026-10-30","start":"2017-01-20"},"retrieval_snapshot":"2026-11-01T14:52:11.274574Z","timeline":[{"count":1,"week":"2017-W03"},{"count":1,"week":"2017-W47"},{"count":1,"week":"2020-W18"},{"count":1,"week":"2020-W35"},{"count":1,"week":"2020-W46"},{"count":1,"week":"2021-W19"},{"count":1,"week":"2021-W30"},{"count":1,"week":"2022-W12"},{"count":1,"week":"2022-W25"},{"count":1,"week":"2022-W39"},{"count":1,"week":"2022-W50"},{"count":1,"week":"2023-W23"},{"count":1,"week":"2024-W17"},{"count":1,"week":"2024-W23"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2024-W47"},{"count":2,"week":"2025-W04"},{"count":2,"week":"2026-W39"},{"count":1,"week":"2026-W41"},{"count":2,"week":"2026-W42"},{"count":32,"week":"2026-W43"},{"count":10,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Gemzar"],"label":"gemcitabine","slug":"gemcitabine"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Xeloda"],"label":"capecitabine","slug":"capecitabine"}],"indications":[{"reason":"Unmapped registry condition: Cholangiocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Gall Bladder Carcinoma","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"ACTICCA-1","aliases":["ACTICCA-1","Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer","Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)"],"brief_title":"Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer","collaborators":["Deutsche Krebshilfe e.V., Bonn (Germany)","Cancer Research UK","Australasian Gastro-Intestinal Trials Group","Dutch Cancer Society"],"conditions":["Cholangiocarcinoma","Gall Bladder Carcinoma"],"display_condition":"biliary tract cancer after curative intent resection","display_interventions":[["gemcitabine","cisplatin"]],"enrollment":{"count":789,"type":"ACTUAL"},"interventions":[{"name":"Gemcitabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Cisplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Capecitabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT02170090","official_title":"Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2025-12","type":"ESTIMATED"},"primary_endpoints":[{"description":"DFS","measure":"Disease free survival (DFS)","timeFrame":"Disease free survival rate at 24 months (DFSR@24)"}],"registered_date":{"date":"2014-06-23","type":"ESTIMATED"},"registry_last_updated":"2025-03-30","registry_url":"https://clinicaltrials.gov/study/NCT02170090","short_name":"ACTICCA-1","short_name_basis":"registry_acronym","sponsor":"Universitätsklinikum Hamburg-Eppendorf","start_date":{"date":"2014-04"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"ACTICCA-1","type":"sponsor_study_id"},{"id":"2024-517340-61-00","type":"ctis"},{"domain":"ANZCTR (clinical trial registry)","id":"ACTRN12615001283561","type":"registry"}],"study_type":"INTERVENTIONAL"}}}